Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0YM7U
|
||||
| Former ID |
DCL000627
|
||||
| Drug Name |
Rituxan Hemotalogy/oncology
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Non-hodgkin's lymphoma [ICD10:C85] | Approved | [1] | ||
| Company |
Genentech
|
||||
| Target and Pathway | |||||
| Target(s) | B-lymphocyte antigen CD20 | Target Info | [2] | ||
| KEGG Pathway | Hematopoietic cell lineage | ||||
| References | |||||
| REF 1 | Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. P T. 2010 March; 35(3): 148-157. | ||||
| REF 2 | Clinical pipeline report, company report or official report of Genentech (2009). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.